MARKET

INVA

INVA

Innoviva
NASDAQ
11.86
-0.21
-1.74%
After Hours: 11.86 0 0.00% 16:59 09/29 EDT
OPEN
11.95
PREV CLOSE
12.07
HIGH
11.95
LOW
11.66
VOLUME
367.79K
TURNOVER
0
52 WEEK HIGH
20.71
52 WEEK LOW
11.57
MARKET CAP
826.71M
P/E (TTM)
9.22
1D
5D
1M
3M
1Y
5Y
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Benzinga · 09/19 18:28
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Benzinga · 09/19 14:56
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BURLINGAME, Calif., September 08, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Off...
Business Wire · 09/08 11:00
Investing in Innoviva (NASDAQ:INVA) three years ago would have delivered you a 16% gain
It hasn't been the best quarter for Innoviva, Inc. ( NASDAQ:INVA ) shareholders, since the share price has fallen 12...
Simply Wall St. · 09/05 15:43
Innoviva Completes Acquisition of La Jolla Pharmaceutical At Average Price Of $6.23 Per Share
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase
Benzinga · 08/22 13:00
Innoviva Completes Acquisition of La Jolla Pharmaceutical
BURLINGAME, Calif., August 22, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and ...
Business Wire · 08/22 12:55
Innoviva's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Innoviva (NASDAQ:INVA) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2.
Benzinga · 08/01 14:10
Innoviva: Q2 Earnings Insights
Innoviva (NASDAQ:INVA) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Innoviva missed estimated earnings by 84.85%, reporting an EPS of $0.05 versus an estimate ...
Benzinga · 07/27 22:09
More
About INVA
Innoviva, Inc. is a holding company. The Company owns a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) collaboration agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI) and an inhaled corticosteroid (ICS), fluticasone furoate (FF). Its TRELEGY ELLIPTA is a once-daily combination medicine consisting of an ICS, long-acting muscarinic antagonist (LAMA) and LABA. Its portfolio also includes sulbactam-durlobactam (SUL-DUR). It also provides GIAPREZA (angiotensin II) and XERAVA (eravacycline).

Webull offers kinds of Innoviva Inc stock information, including NASDAQ:INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.